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The interest in social cognition in schizophrenia is justified by the relationship between deficits in these skills and negative
functional outcomes. Although assessment batteries have already been described, there is no consensus about which measures are
useful in predicting patient functioning or quality of life (QoL). We investigated a set of five measures of recognition of facial
emotions, theory of mind (ToM), and empathy in a cohort of 143 patients with schizophrenia or schizoaffective disorder at inclusion
and, amongst whom 79 were reassessed 1 year later. The distribution was satisfactory for the TREF (Facial Emotion Recognition
Task), V-SIR (Versailles-Situational Intention Reading), and QCAE (Questionnaire of Cognitive and Affective Empathy). Internal
consistency was satisfactory for the TREF, V-SIR, V-Comics (Versailles Intention Attribution Task), and QCAE. Sensitivity to change
was acceptable for the TREF. The TREF and V-SIR showed a cross-sectional relationship with functioning beyond the clinical
symptoms of schizophrenia but not beyond neurocognition. Moreover, the TREF and V-SIR at inclusion could not predict
functioning one year later, whereas most neurocognitive and clinical dimensions at inclusion could. Finally, only affective QCAE
showed a significant cross-sectional, but not longitudinal, association with QoL. In conclusion, the TREF had satisfactory
psychometric properties and showed a cross-sectional, but not longitudinal, association with objective outcome measures, thus
appearing to be reliable in clinical practice and research. The V-SIR also showed promising psychometric properties, despite a
possible weakness to detect change. However, these measures should be interpreted within the context of the good predictive
power of the neurocognitive and clinical status on the outcome.
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INTRODUCTION
The ongoing interest in the constructs of social cognition in
schizophrenia is justified by the relationships between deficits in
these skills and a negative functional outcome1. Several authors
have postulated that social cognition is a distinct construct that
acts as a mediator between cognitive functions and functioning,
despite its close association with neurocognition2,3. In a meta-
analysis, Fett et al.4 reported that social cognitive deficits in
schizophrenia have a greater impact on social functioning than
neurocognitive disorders (i.e., memory, attention, executive
functioning, and speed of processing). Another meta-analysis
showed that social cognition explains a larger portion of the
variance in functioning than neurocognition5. Because of its
importance as a determinant of functional and clinical outcomes,
social cognition could therefore be considered as a cognitive
domain per se, thus justifying its specific evaluation along with
that of neurocognition6. Departing from a single domain
conceptualization, Green et al.7 considered that five constructs
characterize social cognition: perception of emotions, attributional
style, theory of mind (ToM), social perception, and social knowl-
edge. To date, the use of several tools organized within a battery
of tests has been a logical response to the inherent heterogeneity
of these constructs and has encouraged psychometric research to
measure the advantages and weaknesses of candidate measures.
Within a classical psychometric description, an evaluation tool is
expected to meet certain criteria based on its own characteristics:
the results showing a normal distribution, not showing a floor or
ceiling effect, showing satisfactory internal consistency, and
test–retest reliability, and not showing a systematic trend between
test and retest, as evaluated over short periods of time (utility as a
repeated measure). These various psychometric characteristics
have been reported in several studies but have not yet led to a
consensual proposal, although it is acknowledged, however, that
certain instruments may be considered to be acceptable8–11.
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Another important characteristic for evaluating the health
status over a long period is the sensitivity to change (sometimes
called responsiveness). Such sensitivity is defined as the extent to
which an evaluation tool can detect a change when it has
occurred, irrespective of whether the change is meaningful12. It
provides certainty that an improvement measured by an
instrument is due to a true change and not random error13. The
sensitivity to change of the various tools used to assess social
cognition has not yet been investigated in schizophrenia.
Beyond the requirement of being internally adequate, the value
of an assessment tool is also recognized through its properties of
concurrent/divergent validity. Based on the principle that
cognitive deficits causally precede behavior, social cognitive
measures are often assessed for their power to predict outcome
measures, such as real-life functioning. In several types of research,
criterion validity is described as the relationship between the
social cognitive test and an outcome, such as a performance-
based assessment11,14, or real-life functioning8,14.
As mentioned above, social cognition is associated with
neurocognition; these two types of performance both partially
predicting functioning. Consequently, it is informative to char-
acterize incremental validity as the predictive power of a measure
beyond neurocognition. Although most social cognitive measures
included in the SCOPE battery exhibit significant cross-sectional
correlations with certain outcome measures, only a few (ER-40,
Hinting task, and IBT) show additional predictive power beyond
neurocognition11. Such added value was also found for the
DACOBS and TASIT Lies8 but was not supported in another
study14. However, these studies measured the strength of
association between social cognition and functioning using either
a cross-sectional design or during a short period (no longer than
4 weeks). Arguably, a much more extended period would be
required to reveal the action of causal pathways and capture
changes related to disease progression and therapeutic
interventions.
Considering the incomplete information in the literature about
the psychometry of social cognitive measures, the first objective of
the present study was to characterize the properties of a
comprehensive set of social cognitive measures in individuals
with schizophrenia spectrum disorders. Besides distribution-based
psychometric properties, we investigate sensitivity to change
through a 1-year reassessment of patients. The second objective
was to add knowledge on these measures’ predictive capacity of
the outcome. For the first time in our knowledge, functioning and
quality of life (QoL) will be considered cross-sectionally and
longitudinally over one year. Last, we bring thorough insights into
each measure’s predictive power beyond neurocognition thanks
to a complete neuropsychological assessment.
RESULTS
The study included 143 patients with schizophrenia (n= 103) or
schizoaffective disorder (n= 40), who were included between
April 2013 and June 2017. Among them, 79 participants were
reassessed one year later, representing a cohort attrition rate
of 55%.
Description of the population
The population was predominantly male, with an average
educational level between high school and university degrees
(see Table 1). The average total PANSS score indicated mild
symptoms, and the severity of the disorder (CGI) was moderate.
No differences were found between completers and non-
completers for the clinical, neuropsychological, and social-
cognitive profiles at inclusion (see Supplementary Table 1), thus
suggesting a lack of attrition bias in the sample.
Neurocognitive status
Among the participants, 63.6% were evaluated with the WAIS-III
and 36.4% with the WAIS-IV. The neurocognitive performance of
the sample is described in Supplementary Table 2. The most
strongly affected cognitive dimensions were processing speed
(−0.8 ± 0.7 SD), memory (−0.9 ± 0.9 SD), and executive functions
(−1 ± 1.5 SD). Attention (−0.4 ± 0.5 SD), working memory (−0.5 ±
0.7 SD), and reasoning (−0.4 ± 0.9 SD) were strongly less affected.
Psychometric analysis of social cognitive measures
The psychometric data for the EVACO social cognition measures
are summarized in Table 2. The distribution was satisfactory for
three measures: test de reconnaissance des émotions faciales—
facial emotions recognition task (TREF), versailles-situational
intention reading (V-SIR), and questionnaire of cognitive and
affective empathy (QCAE). The two measures of the Social
cognition, Perception, eXecutive functions—goal & belief attribu-
tion sensitivities (SPEX-GBA) test showed a floor effect. Conversely,
the V-Comics suffered from a ceiling effect. All outlier data of the
EVACO battery showed extremely low performance. The two
versions of the V-Comics had the greatest number of outliers (7 for
versions 1 and 2). The V-SIR task, version 1 of the SPEX-GA test,
and cognitive empathy had a small number of outliers (2, 1, and 1,
respectively), whereas the other tasks had none.
Internal consistency was satisfactory for most EVACO tasks: the
TREF with α= 0.76 [0.70–0.82], the V-SIR with α= 0.74 [0.68–0.72],
the V-Comics with α= 0.74 [0.66–0.83] for version 1 and α= 0.83
[0.77–0.88] for version 2, and the QCAE cognitive empathy with α
= 0.87 [0.83–0.90]. Internal consistency was insufficient for the
SPEX-GA test, with α= 0.61 [0.48–0.75] for version 1 and α= 0.31
[0.08–0.55] for version 2, the SPEX-BA test, with α= 0.52
[0.35–0.68] for version 1 and α= 0.38 [0.17–0.60] for version 2,
and QCAE affective empathy, with α= 0.62 [0.53–0.71].
Sensitivity to change
First, we have tested for differences between inclusion and follow-
up in clinical and functional outcomes for participants who
completed both the inclusion and follow-up. Patients showed an
improvement in outcomes related to illness, with a decrease in




Schizo-affective disorder 40 27.3
Mean SD
Age (years) 31.4 8.2
Educational level (years) 12.6 2.4
Premorbid IQ 104 8
Age at onset of illness (years) 21.4 5.6
Duration of untreated psychosis (years) 1.5 3
Total duration of hospitalization (months) 5.9 7.2
PANSS total score 57.6 18.9
Antipsychotics in chlorpromazine equivalents (mg/24 h) 460.7 386.4
CGI severity 4.1 1.4
PSP 52.6 17.5
S-QoL 50.1 19.8
PANSS positive and negative syndrome scale, CGI severity clinical global
impression-severity scale, PSP personal and social performance scale, S-QoL
schizophrenia quality of life questionnaire.
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their symptoms for all PANSS dimensions (paired t tests, p < 0.05)
except excitation (paired t test, p= 0.17). The severity of their
illness decreased (paired t test, p < 0.001), while functioning and
QoL improved (paired t test, p= 0.001; Supplementary Table 3).
This table also reported the correlation of clinical and functional
outcomes between inclusion and follow-up for participants who
completed both evaluations. The sensitivity to change was
medium for the TREF (standardized response mean (SRM)=
0.43), small for the V-SIR and QCAE (see Table 3), and not
investigated for the remaining tools included in the EVACO
battery. The sensitivity to change for the neurocognitive measures
are reported in Supplementary Table 4. Only the global
performance index of TAP-flexibility showed a large sensitivity to
change (SRM= 0.59). The TMT, CPT-IP, TAP-Alterness (SD of
reaction times with alert), TAP-flexibility (number of errors), and
TAP-divided attention (number of errors) all showed moderate
sensitivity to change. The remaining neurocognitive measures that
were reassessed at 1 year showed only small sensitivities to
change.
Cross-sectional relationships between social cognitive
measures and outcomes
Cross-sectional simple regressions for functioning for the various
social cognitive variables showed significant results for the TREF
(ß= 0.32, t(119.8)= 3.7, p < 0.001), V-SIR (after sign reversion: ß=
0.29, t(133.2)= 3.5, p= 0.001), and V-Comics version 1 (ß= 0.38,
t(61.7)= 3.6, p= 0.001). Better performance in social cognition
was associated with better functioning (see Fig. 1, Supplementary
Table 5). Significant associations with functioning were also found
for all neurocognitive variables (0.2 ≤ ß ≤ 0.34, Supplementary
Table 6) and clinical variables (−0.41 ≤ ß ≤−0.25, Supplementary
Table 7).
Hence, we further investigated the relationships between social
cognitive variables and functioning, successively taking into
account clinical variables and neurocognition. First, the TREF, V-
SIR, and V-Comics remained significant predictors of functioning,
regardless of the clinical dimension (positive, negative, disorga-
nization, depression, or excitation) introduced into the model as a
covariate (Supplementary Table 8). Second, the association of
Table 3. Social cognitive performances at inclusion and follow-up and
standardized responses means in individuals who completed both
visits.
Variable Inclusion Follow-up SRM
Mean SD Mean SD
TREF 35.4 6.4 35 8.1 0.43
V-SIR 17.5 6 17.5 6.6 0.01
QCAE affective 2.3 0.4 2.3 0.4 −0.14
QCAE cognitive 2.3 0.3 2.3 0.4 −0.08
SRM standardized response mean, TREF test de reconnaissance des
émotions faciales—facial emotion recognition task, V-SIR versailles-
situational intention reading, QCAE questionnaire of cognitive and affective
empathy.
Fig. 1 ß standardized coefficients of simple cross-sectional
regressions of functioning (PSP) and quality of life (S-QoL) on
various social cognition variables at inclusion. TREF, Test de
Reconnaissance des Émotions Faciales—Facial Emotion Recognition
Test, V-Comics: Versailles Intention Attribution Task, SPEX-GA & BA:
Social cognition, Perception, eXecutive functions—Belief & Goal
Attribution sensitivities, QCAE Cog: Questionnaire of Cognitive and
Affective, QCAE aff: Questionnaire of Cognitive and Affective
Empathy—Affective empathy subscore Empathy—Cognitive empa-
thy subscore, V-SIR: Versailles Situational Intention Reading. The
signs of ß were reversed for V-SIR.
Table 2. Psychometric characteristics of social cognition measures.
Dimension Instrument N Mean SD Floor (%) Ceil (%) Outliers Symmetry coefficient
Facial emotion recognition TREF 114 35.8 5.8 0 0 0 −0.55
Theory of mind SPEX- BA V1 51 1.3 1.3 25.5 11.8 0 −0.58
SPEX- BA V2 51 1.1 1.2 31.4 11.8 0 0.19
SPEX-GA V1 51 1.4 1.3 21.6 19.6 1 (lower) −0.59
SPEX-GA V2 51 1.3 1.1 25.5 11.8 0 0.08
V-SIR 140 17.4 5.9 0 0 2 (higher*) 0.82
V-Comics V1 72 11.6 2.2 2.8 19.4 7 (lower) −0.95
V-Comics V2 71 12.52 1.73 2.8 42.3 7 (lower) −0.97
Self-reported empathy QCAE affective 137 2.29 0.39 0 0 0 −0.27
QCAE cognitive 137 2.29 0.46 0.7 0 1 −0.20
TREF test de reconnaissance des émotions faciales—facial emotions recognition task, SPEX-BA & GA social cognition, perception, eXecutive functions—belief
and goal attribution sensitivities, V-SIR versailles-situational intention reading, V-Comics versailles intention attribution task, QCAE questionnaire of cognitive
and affective empathy, N number of data points, SD standard deviation.
*For V-SIR, higher scores reveal lower performance.
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functioning with the TREF remained significant, regardless of the
neurocognitive dimension included as a covariate (Supplementary
Table 9).
Third, the association of functioning with the V-SIR, which was
significant in the simple analyses, became nonsignificant (p=
0.125) when reasoning was included as a covariate and marginally
significant (p= 0.065) when executive functions were included.
Finally, the association of functioning with the V-Comics version 1
became marginally significant (p= 0.082) when reasoning was
included as a covariate.
Among social-cognitive predictors, only the affective score of
the QCAE exhibited a significant relationship with QoL (ß= 0.17, t
(134.3)= 2, p= 0.044), the cognitive score being marginally
negatively significantly related (ß=−0.16, t(131.7)=−1.8, p=
0.07, see Fig. 1, Supplementary Table 10). No cognitive variable
showed a significant relationship with QoL (Supplementary Table
11). There were significant negative relationships of QoL with
positive, negative, and depression PANSS scores, but not with
disorganization nor excitation (Supplementary Table 12).
We explored the relationships of affective QCAE with QoL,
introducing clinical covariates to find potential confounders
(Supplementary Table 13). The link between affective QCAE and
QoL became non-significant when depression was introduced as a
covariate. This link became marginally significant with positive
and negative dimensions as covariates and remained significant
with disorganization and excitation as covariates.
Predicted 1-year outcome
Simple longitudinal regressions of functioning at follow-up on
social cognition at inclusion showed significant results only for the
V-Comics version 1 (ß= 0.33, t(40.3)= 2.6, p= 0.013), with good
skills in ToM at inclusion related to better functioning at one year
(see Fig. 2, Supplementary Table 14). In contrast, regression of
functioning at follow-up on neurocognitive variables at inclusion
gave more consistent results, with significant positive associations
for all neurocognitive dimensions, except memory (Supplemen-
tary Table 15). Similarly, most baseline clinical dimensions (PANSS
positive, disorganization, excitation, and depression but not
negative dimension) showed significant negative relationships
with functioning at follow-up (Supplementary Table 16). Function-
ing at follow-up was also predicted by functioning and QoL at
inclusion (Supplementary Table 16).
The prediction of functioning at follow-up by social cognition at
inclusion beyond neurocognition at inclusion is summarized in
Supplementary Table 17. The prediction of functioning at follow-
up by the V-Comics version 1 at inclusion became insignificant
when almost any neurocognitive domain was included as a
covariate (processing speed, working memory, reasoning, and
executive functions), except for memory, for which the relation-
ship became marginally significant. Finally, the prediction of
functioning at follow-up by version 1 of the V-Comics at inclusion
became marginally significant when the positive disorganization
and excitation dimensions were included as covariates. The
association remained significant when negative symptoms,
depression, and QoL were included as covariates. The association
became nonsignificant when functioning at inclusion was
introduced as a covariate (Supplementary Table 18).
There was no relationship between social cognition variables at
inclusion and QoL at 1 year (see Fig. 2, Supplementary Table 19).
The same negative findings were found for neurocognitive
variables (Supplementary Table 20).
DISCUSSION
The objective of this study was to characterize the psychometric
properties of a set of social cognitive measurements, administered
as a battery to a population of individuals with schizophrenia
spectrum disorders in a longitudinal design and to assess its
relevance to predict outcome measures, such as functioning
and QoL.
The psychometric characteristics of EVACO instruments are
summarized in Table 4. The distribution analysis suggests that the
TREF, V-SIR, and QCAE allow good discrimination between
individuals, with few outliers. The floor effect for the SPeX-GBA
test suggests that the task was too difficult, whereas the V-Comics
ceiling effect indicates that the task was too easy, in agreement
with the results of a previous study9. The V-Comics also suffered
from a large number of extremely low performances, which may
have been facilitated by its ceiling effect. The results showed good
internal consistency for all EVACO tasks, except the SPEX-GBA test
and affective subscale of the QCAE.
Among the tools we investigated in the EVACO battery, only the
TREF showed sufficient sensitivity to change. Several confounding
factors may explain the low sensitivity to change found for the V-
SIR and QCAE rather than psychometric flaws in these tools. The
first factor could be a lack of change in ToM and empathy in the
recruited sample. However, this explanation seems unlikely, as
schizophrenia symptoms and functioning improved during the
follow-up in our study. Indeed, better ToM was previously shown
to be associated with lower symptoms and better functioning15,16.
Similar results were also found for empathy17–19. The second
factor could be the considerable heterogeneity in the changes of
the scores, which may have led to a small SRM and an
underestimation of sensitivity to change. Impairment of social
cognition is heterogeneous in schizophrenia20, which may lead to
its heterogeneous course. Further studies investigating sensitivity
to change in social cognitive measures should attempt to recruit
homogenous samples according to the individual magnitude of
social cognition change. Third, the poor sensitivity to change
found for the V-SIR and QCAE may be explained by low test-retest
reliability, which was not investigated in this study. Reliability is
closely associated with sensitivity to change, as tools that are
prone to higher variability between assessments may detect less
change than those with lower between-assessment variability.
Finally, practice effects may interfere with the ability to measure
changes in cognition, at least in designs based on several
administrations of cognitive tests21,22. However, the intervals
between evaluations in these previous studies were much shorter
than the 1-year follow-up used in this study. This study confirms a
previous report that patients followed in the FACE-SZ cohort
Fig. 2 ß standardized coefficients of simple regressions of
functioning (PSP) and quality of life (S-QoL) at follow-up on
various social cognition measures at inclusion. Legends: please see
Fig. 1.
E. Brunet-Gouet et al.
4
npj Schizophrenia (2021)    30 Published in partnership with the Schizophrenia International Research Society
showed a clinical (positive and negative symptoms, depression,
insight, and suicidality) and functional improvement in the first
year of follow-up23. Increased access to psychosocial rehabilitation
interventions such as psychoeducation and cognitive remediation
has been associated with an improvement in positive and
negative symptoms, neurocognition and functioning in this
cohort24. Another source of improvement for patients followed
in the FondaMental Advanced Centres of Expertize may also be
the suggestion of personalized medication adjustment in order to
follow as closely up-to-date international recommendations.
The recognition of emotions, assessed using the TREF, was
positively associated with functioning beyond neurocognition and
symptoms. This result is consistent with previous reports that
showed associations between the recognition of emotions, as
measured by the ER-40 and BLERT tasks, and functioning beyond
neurocognition8,11,25.
Among the three tools that evaluate ToM, the V-SIR and V-
Comics version 1 showed cross-sectional relationships with
functioning beyond symptoms of schizophrenia but not beyond
reasoning. Our results are consistent with a meta-analysis that
estimated the correlation between ToM and reasoning abilities to
be 0.30, corresponding to approximately 10% of common
variance26. Moreover, another meta-analysis showed reasoning
abilities and functioning to exhibit correlation coefficients ranging
from 0.08 for community functioning to 0.3 for social problem
solving5.
The SCOPE study also found an association between ToM
(measured by the Hinting Task and RMET) and functioning, but
only the Hinting Task showed an association with functioning
beyond neurocognition11. Davidson et al.8 included the V-Comics
in their battery and, contrary to our study, did not report such an
association with functioning. However, they did not split the task
into two versions, and the association that we found was
significant for only one.
On the other hand, the SPeX-GBA test, of which the
psychometric properties are weaker than those of the other tasks,
did not show any association with functioning. Therefore, it does
not appear adequate to be included in a social cognition battery.
Finally, as assessed by the QCAE, empathetic dispositions did not
show a significant association with functioning, contrary to the
results reported for the SCAF battery14. However, the
measurement of empathy in that battery was made using a very
different paradigm, closer to a ToM task.
Overall, almost all neurocognitive and clinical variables were
associated with functioning in our study. The most predictive
neurocognitive dimensions of functioning were, in decreasing
order: executive function, reasoning, processing speed, attention,
and working memory. Our results suggest that impairments in
neurocognition and social cognition share a common variance in
their association with functioning. Nevertheless, specific social
cognitive measures provide additional information on functioning
determinants when added to the neurocognitive and clinical
status.
The TREF predicted functioning at one year but not beyond
neurocognition. Our results suggest that functioning at follow-up
is weakly predicted by social-cognitive measures at inclusion, with
only one measure among 10 (V-Comics version 1) being
associated with functioning. In contrast, functioning at follow-up
was more consistently predicted by neurocognition and symp-
toms of schizophrenia at inclusion. Moreover, the predictive
power of the V-Comics version 1 at baseline on functioning one
year later was mainly explained by neurocognition and function-
ing at baseline. In particular, reasoning, executive functions, and
working memory appear to explain the longitudinal link between
social cognition and functioning. This may be related to the results
of Hoe et al. They used latent difference analysis, and their final
multivariate model suggested that baseline neurocognition
predicts changes in social cognition at one year, as well as
changes in psychosocial functioning27. In contrast, baseline social
cognition did not predict functioning one year later. These results
suggest that the upward causal influence of social cognition in
predicting functional outcome fully overlaps with neurocognition.
In the present study, the patients’ QoL was not predicted by any
social cognitive or neurocognitive measures, except for self-
reported affective empathy (QCAE). The literature provides
conflicting results concerning the impact of cognitive processes
and empathic dispositions on QoL. Several authors found a
positive association between cognitive performance and QoL28–31,
whereas others found a negative32–34 or non-significant associa-
tion35,36. The negative results found for the V-SIR are also
consistent with those of a previous study using the same
schizophrenia quality-of-life questionnaire (S-QoL) scale37. Since
the measures have in common the fact that they are
Table 4. Synthesis of the psychometric properties of each tool used in the EVACO battery.






SPEX- BA V1 NA NA A NA U NA NA
SPEX- BA V2 NA NA A NA U NA NA
SPEX- GA V1 NA NA NA NA U NA NA
SPEX- GA V2 NA NA A NA U NA NA
TREF A A A A A Aa,b NA
V-SIR A A A A NA Ab NA
V-Comics V1 NA A NA A U Ab A
V-Comics V2 NA A NA A U NA NA
QCAE affective A A A NA NA Ac NA
QCAE cognitive A A A A NA NA NA
A acceptable, NA not acceptable, U unknown,
aSignificant relationship with quality of life.
bSignificant relationship beyond neurocognition.
cSignificant relationship beyond symptoms.
SPEX-BA & GA social cognition, perception, executive functions—belief & goal attribution sensitivities, TREF test de reconnaissance des émotions faciales—facial
emotions recognition task, V-SIR versailles-situational intention reading, V-Comics versailles intention attribution task, QCAE questionnaire of cognitive and
affective empathy.
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self-assessments, an explanatory hypothesis for their common
variance could be an undifferentiated effect of this modality.
The following limitation in this study has to be considered. The
sample size might have lacked some power, particularly for tools
that were divided into two versions (SPEX and V-Comics).
Moreover, some instruments, SPEX and TREF, had a higher
proportion of missing data than others due to a lack of instrument
availability in some centers when the inclusions began. Further
study should gather together the instruments selected by the
different social-cognitive batteries described in the literature and
assess which minimal tool combination captures the optimal
amount of social cognition variance using step-wise regression
analysis. This study suffers from a 12-month attrition rate of
approximately 46%, raising the question of possible bias in the
results. We have no information on the reasons for this. However,
comparisons of patients’ clinical, neurocognitive, and social-
cognitive characteristics according to whether or not they
completed the second assessment did not show any difference
that would bias the results. Moreover, lower power cannot explain
the lower social-cognitive instruments’ ability to predict function-
ing longitudinally compared to transversal associations. As long-
itudinal regressions analyses were run after estimating the missing
data by multiple imputations, the sample sizes were identical in
transversal and longitudinal regression analyses.
To conclude, our results highlight the satisfactory psychometric
properties of one measurement from the EVACO battery, the TREF,
which showed cross-sectional, but not longitudinal, associations
with objective outcome measures beyond symptoms and
neurocognition. The TREF thus appears to be reliable for use in
clinical practice and research. The V-SIR also shows promising
psychometric properties, despite possible weaknesses in the
associations with functioning beyond neurocognition and detect-
ing change. The association between social cognition and
functioning appears largely explained by specific neurocognitive
dimensions, mainly executive function and reasoning, but not
clinical symptoms. In contrast, the results of social cognition tests
appear to not correlate with QoL, which instead may be associated
with self-reported empathetic skills. The evaluation of this
construct may be particularly relevant for clinical or research
purposes when the outcome of interest depends on the patient’s
subjective complaints and not solely on objective capacity.
METHODS
Procedure
In this multicenter longitudinal study (NCT02901015, previously registered
at ClinicalTrial under number NCT02901015), patients were recruited from
seven Centers of Expertize for schizophrenia (Clermont-Ferrand, Créteil,
Grenoble, Marseille, Montpellier, Strasbourg, and Versailles), making up a
network established by the FondaMental Foundation. Patients were
referred by their general practitioners or psychiatrists. The local medical
ethics committee (Comité de Protection des Personnes Ile-de-France XI)
approved the study (2012-A00387-36). Each participant gave written
informed consent before inclusion and received an indemnity.
Participants
The primary criterion for inclusion was the presence of schizophrenia or
schizoaffective disorder for which the diagnosis was based on a structured
clinical interview according to the DSM4-TR (Diagnostic and Statistical
Manual of Mental Disorder. 4th edition, revised) criteria38. Senior
psychiatrists or psychologists conducted the clinical interviews focused
on schizophrenia. The patients were between 15 and 65 years of age. The
exclusion criteria were current hospitalization in psychiatry or a change in
treatment within the last four weeks, substance dependence at the time of
assessment (except tobacco), electroconvulsive therapy (for less than
6 months), neurological lesions or pathology that may have significantly
influenced cognitive abilities, and significant sensory impairment. Subjects
who were unable to attend the various assessments or planned to change
their medical follow-up within the following year were also excluded.
Participants were assessed at inclusion and one year later.
Clinical assessment
All the tools and questionnaires were administered by trained clinicians
from the different centers. The same clinicians did the evaluations at
baseline and follow-up for 96.2% of patients. At least one meeting was
organized per year in order to harmonize interrater reliability in clinical
assessment between the different centers involved in the recruitment
network.
The severity of schizophrenic symptoms was assessed using the Positive
and Negative Syndrome Scale (PANSS)39. Five PANSS sub-scores were
calculated: positive, negative, disorganization, arousal, and depressive
symptoms40. The PANSS has good internal consistency (Cronbach’s α - CA:
0.73–0.83)39 and acceptable interrater reliability (intraclass correlation
coefficient—ICC: 0.56–0.80)41. The Clinical Global Impression-Severity Scale
(CGI-S) assessed the severity of the schizophrenic spectrum disorder42.
Assessment of social cognition
Social cognition was evaluated with a battery (EVACO) of tests and a self-
evaluation administered by trained neuropsychologists43. The authors
selected the tools by considering each paradigm’s characteristics in terms
of the tested psychological construct to be the most exhaustive as
possible. We included tests that assessed several mental state categories
(attribution of intentions, beliefs, and affective and emotional states to
others), several attributional stances (3rd person and self-assessment), and
several stimuli modalities (static and animated visuals, verbal, and
nonverbal content).
To assess facial emotion recognition, the TREF44 consists of 54 color
photographs of actors’ faces presented on a computer screen. Each picture
is displayed for 10 s and depicts an emotion with nine degrees of
expressive intensity, obtained by image morphing transformation. The
participant must then choose from among six emotions (fear, sadness,
contempt, anger, joy, or disgust) that best represent what the actor may be
feeling. We used the average accuracy overall conditions.
Theory-of-mind was assessed with V-Comics (Versailles Intention
Attribution Task)45 that is composed of short comic strips in which the
person has to find the most logical ending by choosing among three
propositions (one right answer, two wrong answers). This task is composed
of three conditions: attribution of an intention to others and under-
standing physical causality, with or without characters. This task was
divided into two versions of equal length (by matching the difficulty of the
two versions based on previous results) to produce two alternative
versions for test-retest intervention protocols and avoid a learning effect.
Each of the two versions has 20 items for the physical logic control
condition and 14 items for the intention attribution experimental
condition. We used the average accuracy in the intention attribution
experimental condition.
The V-SIR46 task consists of eight short videos that elicit theory-of-mind
judgments. The participant has to judge the degree of probability of four
propositions explaining one of the characters’ intentions. This judgment is
made on a four-level Likert scale. The score used is the average distance
between the participant’s responses and those of a group of control
subjects described in a previous study46. Higher scores represent lower
ToM performance.
The SPEX-GBA theory-of-mind test consists of eight scenarios in the form
of silent animations47. They are divided among five conditions to evaluate
the ability of the test subject to attribute physical causes to an event and
the goals and beliefs of a character. As for V-COMICS, this task was divided
into two versions of equal length. Each version has 20 items (12 to assess
the attribution of goals and beliefs to a character, 8 to assess the
attribution of physical causality). In the analyses, only the 12 items
assessing the attribution of goals and beliefs were considered. The
sensitivity of goal and belief attribution was calculated from these 12 items
as described in Supplementary Information 1.
Last, the QCAE48 is a self-administered questionnaire consisting of 31
questions that assess empathic dispositions in their cognitive and affective
dimensions on a four-level Lickert agreement scale. The average score
across all items for the affective and cognitive subscales was used as
defined by the authors.
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Assessment of neurocognition
Six domains of neurocognition were evaluated at inclusion (Supplemen-
tary Information 2): processing speed, attention/vigilance, working
memory, memory, reasoning, and executive functions. For each domain,
higher scores reflected better performance after normalization.
Assessment of outcome
Based on a clinical interview, social functioning was assessed using the
personal and social performance scale (PSP)49, which provides an assessment
of four domains (usual social activities, social and work relationships, self-
maintenance, and disruptive and aggressive behaviors). Scores range from 0
to 100, higher scores reflecting better functioning. PSP score is computed
from graded severity levels in each domain, all of which being combined into
a broad score and then adjusted thanks to the overall opinion of the rater on
other domains of social function. The scale has shown acceptable internal
consistency (CA, 0.76)50 and excellent interrater reliability (ICC, 0.97)51.
QoL was assessed using the S-QoL 1852, a self-assessment scale with
eight factors: psychological well-being, physical well-being, self-esteem,
family relationships, relationships with friends, resilience, autonomy, and
emotional life. Higher scores reflect a better QoL. Cronbach alpha
coefficient is satisfactory 0.72–0.9.
Statistics
The distributions of each baseline measure of social cognition were tested
for normality, the presence of outliers, ceiling or floor effects, and internal
consistency. Sensitivity to change between baseline and follow-up was also
assessed with the SRM. This characteristic was computed only for
participants who completed the inclusion and follow-up and not calculated
for tests administered in two different versions at inclusion and follow-up.
The relationships between social cognition variables, functioning, and
QoL were explored first at the inclusion visit, and then longitudinally
between inclusion and follow-up, after estimating the missing data by
multiple imputations (50 imputations, Markoff chain equations) using the
MICE package in R53.
Simple cross-sectional relationships between social cognition and
outcome measures (i.e., functioning, PSP, QoL, and S-QoL) at inclusion
were explored using successive univariate linear regressions. Multiple
variable linear regression analyses were conducted to determine whether
the previously identified links could resist the introduction of covariates
using the same variables as those previously described, along with the
alternate introduction of neurocognitive covariates and clinical covariates
(the various PANSS subscores). In these multiple analyses, every single
social-cognitive tool was investigated separately, as we were interested in
making recommendations about their single-use in a clinical context
beyond usually available information such as clinical and neurocognitive
profile. Each tool’s predictive power for the functioning (PSP) and QoL (S-
QoL) at one year was explored similarly, except that the dependent
outcome variables were taken at follow-up.
Standardized coefficients ß were determined for all regression analyses.
For all results, positive ß and t-statistics indicated that better social
cognitive performance was associated with a better outcome. More details
on the statistics and criteria for defining satisfactory characteristics can be
found in Supplementary Information 3.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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